These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8907719)

  • 1. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
    Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
    Sugahara M; Kiriyama A; Hamada Y; Kiso Y; Takada K
    Biopharm Drug Dispos; 1995 May; 16(4):269-77. PubMed ID: 7548776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
    Kiriyama A; Mimoto T; Kisanuki S; Kiso Y; Takada K
    Biopharm Drug Dispos; 1993 Nov; 14(8):697-707. PubMed ID: 8305629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
    Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
    J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
    Lin JH; Chen IW; Vastag KJ; Ostovic D
    Drug Metab Dispos; 1995 Jul; 23(7):730-5. PubMed ID: 7587962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a colonic release capsule dosage form and the absorption of insulin.
    Kraeling ME; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1992 Apr; 14(3):199-209. PubMed ID: 1378164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
    Fung HB; Kirschenbaum HL; Hameed R
    Clin Ther; 2000 May; 22(5):549-72. PubMed ID: 10868554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
    Kiriyama A; Mimoto T; Kiso Y; Takada K
    Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
    Kiriyama A; Fujita K; Takemura S; Kuramoto H; Kiso Y; Takada K
    Biopharm Drug Dispos; 1994 Oct; 15(7):617-26. PubMed ID: 7849237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
    Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
    Vertzoni M; Valsami G; Reppas C
    J Pharm Pharmacol; 2006 Sep; 58(9):1211-7. PubMed ID: 16945179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs.
    Takaya T; Ikeda C; Imagawa N; Niwa K; Takada K
    J Pharm Pharmacol; 1995 Jun; 47(6):474-8. PubMed ID: 7545751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
    Kiriyama A; Nishiura T; Yamaji H; Takada K
    Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms].
    Neve J; Hanocq M; Peretz A; Abi Khalil F; Pelen F
    J Pharm Belg; 1993; 48(1):5-11. PubMed ID: 8483101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adsorbents on the absorption of lansoprazole with surfactant.
    Ito Y; Arai H; Uchino K; Iwasaki K; Shibata N; Takada K
    Int J Pharm; 2005 Jan; 289(1-2):69-77. PubMed ID: 15652200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study.
    Bours MJ; Bos HJ; Meddings JB; Brummer RJ; van den Brandt PA; Dagnelie PC
    BMC Gastroenterol; 2007 Jun; 7():23. PubMed ID: 17578566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.